Browse the corpus

Clozapine is an FDA-approved atypical antipsychotic medication for treatment-resistant schizophrenia. Clozapine is not the first-line drug of choice due to its range of adverse effects, making compliance an issue for many patients. However, clozapine also has some advantages, including lowering the risk of suicide and tardive dyskinesia and fewer relapses. Regarding suicide risk, clozapine has been demonstrated to reduce suicidal behavior even in non-treatment-resistant schizophrenia and patients with schizoaffective disorder. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of clozapine pertinent for members of the interprofessional team where this agent is indicated. Objectives: Identify appropriate candidates for clozapine therapy based on treatment-resistant schizophrenia or recurrent suicidal behavior. Differentiate between the unique pharmacological profile of clozapine and other antipsychotic medications, including its superior efficacy in treatment-resistant cases. Assess treatment response and optimize the dosage of clozapine to achieve the desired therapeutic outcomes while minimizing adverse effects. Collaborate with other interprofessional healthcare team members, such as pharmacists and laboratory staff, to ensure the safe and effective use of clozapine. Access free multiple choice questions on this topic.

The reported mortality rate of clozapine intoxication is approximately 12%.[31] A 36-year-old man experienced rhabdomyolysis following an overdose of clozapine 125 mg tablets. After 5 days, the patient was discharged from the hospital when the creatinine kinase levels returned within normal range. Monitor creatinine kinase levels to diagnose possible rhabdomyolysis.[32] Another acute overdose in a 60-year-old man reported venous thromboembolism and pulmonary embolism; therefore, it is essential to monitor patients initiated on clozapine who may be at an increased risk of thromboembolic events.[33] The common adverse events associated with clozapine overdose are hypersalivation, tachycardia, hypotension, sedation, delirium, coma, respiratory depression, or failure. There are few reports of cardiac arrhythmias, aspiration pneumonia, and seizure. Fatality is reported at doses above 2500 mg; however, some patients recovered after ingesting 4000 mg of clozapine. Management There is a lack of a specific antidote to an overdose of clozapine. Monitor and maintain an airway, ventilation, cardiac status, and vital signs, and provide symptomatic and supportive measures. Consider the possibility of multiple-drug overdose and contact the Poison Control Center to report and get information on additional management (1-800-222-1222).

Clozapine, due to its many lethal adverse reactions, has become a drug that many clinicians are afraid to prescribe due to fear of patient safety. Psychiatrists prescribe clozapine in supervised settings to patients with a risk of suicide. Nursing staff should monitor the patients for compliance. Pharmacists should perform thorough medication reconciliation and report adverse effects to clinicians. One of the most significant concerns for clozapine is the adverse effect of agranulocytosis, which requires cessation of therapy and hematology consultation. Serious infection resulting from agranulocytosis may require infectious disease consultation. Cardiologist input is crucial for myocarditis. Clozapine poisoning requires rapid stabilization by the critical care team and consultation medical toxicologist. The FDA has mandated a national registry to monitor weekly white blood cell count levels for anyone prescribed clozapine. There are many limitations to clozapine use, described in a systematic review looking at barriers to its use. Barriers described in the study are the patient, the clinician, and health-system-related barriers. Patient barriers encompass noncompliance with weekly blood draws, intolerance to clozapine adverse effects, and the management complexities associated with multiple prescribed drugs. From the clinician's standpoint, barriers encompass inadequate experience and knowledge in prescribing clozapine, fear of side effects, non-adherence to guidelines, the necessity for intense monitoring, and perceptions of patient non-compliance; systemic issues involve insufficient resources like staffing and nurses, a shortage of beds, and service fragmentation. Addressing these challenges requires the implementation of point-of-care devices, educational interventions for both clinicians and patients, and shared decision-making, with the effectiveness of these solutions necessitating evaluation through controlled study designs.[34] A collaborative healthcare team comprising clinicians, including psychiatric specialists and pharmacists, employing open communication, shared patient data, and collaborative treatment strategies, has the potential to enhance therapeutic efficacy and optimize treatment outcomes associated with clozapine therapy.